Richard Bergström takes DG role at EFPIA
pharmafile | March 18, 2011 | Appointment | Research and Development, Sales and Marketing | Brian Ager, EFPIA, Richard Bergstrom, appointment, research and development, sales and marketing
European pharma industry association EFPIA has appointed Richard Bergström as its new director general.
He takes over from Brian Ager, who is leaving to join the European Round Table of Industrialists as secretary general.
Andrew Witty, GlaxoSmithKline chief executive and EFPIA president, said: “We are delighted that Richard will be EFPIA’s new director general; his experience and approach are exactly what we need at this time. I am confident he will lead the continued transformation of EFPIA into a valued partner to all its stakeholders.
“On behalf of the EFPIA membership, I would also like to thank Brian Ager for his leadership and dedication over the last 16 years. We sincerely wish him well in his new role.”
Richard, who will join EFPIA on 1 April, is currently director general of Swedish pharma body LIF and vice-chairman of the board of the Karolinska Institutet.
He said: “The research-based pharmaceutical industry can make a major contribution in progressing some of Europe’s most important objectives, including improved economic competitiveness, better healthcare for all citizens, and an ageing population that enjoys a high quality of life.”
A pharmacist by training, he began his career at the Swedish Medical Products Agency and subsequently held senior regulatory affairs positions at Roche and Novartis.
Richard has been a member of the EFPIA Board for a number of years, and chairs its Trust Committee and its Task Force on Health Technology Assessment. He is also a Council member of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA).
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …
